Well that would certainly make for a great discussion, as Golf has produced a list of about 21 or so different potential diseases and ailments that apabetalone may target one day! I like them both, but the following sure sounds positive for Zenith shareholders and has me wondering when BP will finally pull the trigger?

Two quotes from Don based on Imtesty's AGM transcript:

So we are very excited with the progress that has been made on the clinical side here. And we have been in discussions also with Zenith with major pharmaceutical companies in detail as to where this is and where it’s going. And it’s exciting. Stay tuned on this one. It’s got some wheels going right now.

And:

So we’re pretty excited. It’s been a really really good year at Zenith and the amount of attention that we’re getting from the majors and the cancer conferences and people who want to partner their drug, because they don’t have to change drugs, they don’t have to change horses so to speak. They can keep their existing programs, make them last longer and generate more money and have better results for their patients.